Latest Developments in the Management of Nut Allergies

H. A. Brough; R. Gourgey; S. Radulovic; J. C. Caubet; G. Lack; A. Anagnostou

doi:10.1007/s40521-021-00290-2

Latest Developments in the Management of Nut Allergies

H. A. Brough^*, R. Gourgey, S. Radulovic, J. C. Caubet, G. Lack, A. Anagnostou

^*Corresponding author for this work

Women & Children's Health

Research output: Contribution to journal › Review article › peer-review

3 Citations (Scopus)

Abstract

Purpose of review: In this review, we sought to describe the most recent advances in the dietary and medical management of peanut and tree nut allergy, including selective introduction and immunotherapy. Recent findings: Dietary updates include changes to labeling laws, improved information sources, and new apps for buying foods in shops and overseas to better protect individuals with nut allergies. There are still issues in the management of nut allergies in schools, such as parents having to resort to packed lunches instead of school meals and patients experiencing bullying. Air travel also poses concern, but additional resources are now available to travelers, and recent evidence suggest limited airborne exposure to nuts. The medical management of anaphylaxis is use of epinephrine; however, this remains underutilized. Needle length and administration devices have been recently debated considering the risk of bone penetration vs subcutaneous administration, and autoinjectors seem to deliver higher peak concentrations than syringes. Selective nut introduction has gained momentum in the last 5 years, demonstrating improved quality of life but with the need for motivated parents for continued consumption and available resources for challenges. Immunotherapy to nuts is also a rapidly developing field, with the balance of efficacy and safety being important considerations in the differing modes of administration. Summary: The management of nut allergies is a rapidly developing field, and dietary and medical management have progressed significantly in the last 5 years. Future research directions include improving safety and efficacy of food immunotherapy and examining patients’ goals for therapy and treatment outcomes.

Original language	English
Pages (from-to)	97-110
Number of pages	14
Journal	Current Treatment Options in Allergy
Volume	8
Issue number	2
DOIs	https://doi.org/10.1007/s40521-021-00290-2
Publication status	Published - Jun 2021

Keywords

Dietary management
Epinephrine
Food immunotherapy
Nut allergy

Access to Document

10.1007/s40521-021-00290-2

Cite this

@article{048254cf098a4684ad8816748e079c78,

title = "Latest Developments in the Management of Nut Allergies",

abstract = "Purpose of review: In this review, we sought to describe the most recent advances in the dietary and medical management of peanut and tree nut allergy, including selective introduction and immunotherapy. Recent findings: Dietary updates include changes to labeling laws, improved information sources, and new apps for buying foods in shops and overseas to better protect individuals with nut allergies. There are still issues in the management of nut allergies in schools, such as parents having to resort to packed lunches instead of school meals and patients experiencing bullying. Air travel also poses concern, but additional resources are now available to travelers, and recent evidence suggest limited airborne exposure to nuts. The medical management of anaphylaxis is use of epinephrine; however, this remains underutilized. Needle length and administration devices have been recently debated considering the risk of bone penetration vs subcutaneous administration, and autoinjectors seem to deliver higher peak concentrations than syringes. Selective nut introduction has gained momentum in the last 5 years, demonstrating improved quality of life but with the need for motivated parents for continued consumption and available resources for challenges. Immunotherapy to nuts is also a rapidly developing field, with the balance of efficacy and safety being important considerations in the differing modes of administration. Summary: The management of nut allergies is a rapidly developing field, and dietary and medical management have progressed significantly in the last 5 years. Future research directions include improving safety and efficacy of food immunotherapy and examining patients{\textquoteright} goals for therapy and treatment outcomes.",

keywords = "Dietary management, Epinephrine, Food immunotherapy, Nut allergy",

author = "Brough, {H. A.} and R. Gourgey and S. Radulovic and Caubet, {J. C.} and G. Lack and A. Anagnostou",

note = "Funding Information: AA is the Principal Investigator for Aimmune Therapeutics phase III peanut oral immunotherapy trials and receives Institutional Funding. HB reports grants from National Institute of Allergy and Infectious Diseases (NIAID, NIH) subinvestigator for research by Aimmune and DBV Technologies and speaker honoraria from DBV Technologies and Sanofi. JC has received speaker honoraria from ThermoFisher Scientific. GL reports grants from National Institute of Allergy and Infectious Diseases (NIAID, NIH), Food Allergy & Research Education (FARE), MRC & Asthma UK Centre, UK Dept of Health through NIHR, National Peanut Board (NPB), UK Food Standards Agency (FSA), and The Davis Foundation during the conduct of the study and shareholder in DBV Technologies and Mighty Mission Me and scientific advisor for Novartis, Sanofi-Genyzme, Regeneron, and ALK-Abello. Publisher Copyright: {\textcopyright} 2021, Crown. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = jun,

doi = "10.1007/s40521-021-00290-2",

language = "English",

volume = "8",

pages = "97--110",

journal = "Current Treatment Options in Allergy",

issn = "2196-3053",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - Latest Developments in the Management of Nut Allergies

AU - Brough, H. A.

AU - Gourgey, R.

AU - Radulovic, S.

AU - Caubet, J. C.

AU - Lack, G.

AU - Anagnostou, A.

N1 - Funding Information: AA is the Principal Investigator for Aimmune Therapeutics phase III peanut oral immunotherapy trials and receives Institutional Funding. HB reports grants from National Institute of Allergy and Infectious Diseases (NIAID, NIH) subinvestigator for research by Aimmune and DBV Technologies and speaker honoraria from DBV Technologies and Sanofi. JC has received speaker honoraria from ThermoFisher Scientific. GL reports grants from National Institute of Allergy and Infectious Diseases (NIAID, NIH), Food Allergy & Research Education (FARE), MRC & Asthma UK Centre, UK Dept of Health through NIHR, National Peanut Board (NPB), UK Food Standards Agency (FSA), and The Davis Foundation during the conduct of the study and shareholder in DBV Technologies and Mighty Mission Me and scientific advisor for Novartis, Sanofi-Genyzme, Regeneron, and ALK-Abello. Publisher Copyright: © 2021, Crown. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/6

Y1 - 2021/6

N2 - Purpose of review: In this review, we sought to describe the most recent advances in the dietary and medical management of peanut and tree nut allergy, including selective introduction and immunotherapy. Recent findings: Dietary updates include changes to labeling laws, improved information sources, and new apps for buying foods in shops and overseas to better protect individuals with nut allergies. There are still issues in the management of nut allergies in schools, such as parents having to resort to packed lunches instead of school meals and patients experiencing bullying. Air travel also poses concern, but additional resources are now available to travelers, and recent evidence suggest limited airborne exposure to nuts. The medical management of anaphylaxis is use of epinephrine; however, this remains underutilized. Needle length and administration devices have been recently debated considering the risk of bone penetration vs subcutaneous administration, and autoinjectors seem to deliver higher peak concentrations than syringes. Selective nut introduction has gained momentum in the last 5 years, demonstrating improved quality of life but with the need for motivated parents for continued consumption and available resources for challenges. Immunotherapy to nuts is also a rapidly developing field, with the balance of efficacy and safety being important considerations in the differing modes of administration. Summary: The management of nut allergies is a rapidly developing field, and dietary and medical management have progressed significantly in the last 5 years. Future research directions include improving safety and efficacy of food immunotherapy and examining patients’ goals for therapy and treatment outcomes.

AB - Purpose of review: In this review, we sought to describe the most recent advances in the dietary and medical management of peanut and tree nut allergy, including selective introduction and immunotherapy. Recent findings: Dietary updates include changes to labeling laws, improved information sources, and new apps for buying foods in shops and overseas to better protect individuals with nut allergies. There are still issues in the management of nut allergies in schools, such as parents having to resort to packed lunches instead of school meals and patients experiencing bullying. Air travel also poses concern, but additional resources are now available to travelers, and recent evidence suggest limited airborne exposure to nuts. The medical management of anaphylaxis is use of epinephrine; however, this remains underutilized. Needle length and administration devices have been recently debated considering the risk of bone penetration vs subcutaneous administration, and autoinjectors seem to deliver higher peak concentrations than syringes. Selective nut introduction has gained momentum in the last 5 years, demonstrating improved quality of life but with the need for motivated parents for continued consumption and available resources for challenges. Immunotherapy to nuts is also a rapidly developing field, with the balance of efficacy and safety being important considerations in the differing modes of administration. Summary: The management of nut allergies is a rapidly developing field, and dietary and medical management have progressed significantly in the last 5 years. Future research directions include improving safety and efficacy of food immunotherapy and examining patients’ goals for therapy and treatment outcomes.

KW - Dietary management

KW - Epinephrine

KW - Food immunotherapy

KW - Nut allergy

UR - http://www.scopus.com/inward/record.url?scp=85107910708&partnerID=8YFLogxK

U2 - 10.1007/s40521-021-00290-2

DO - 10.1007/s40521-021-00290-2

M3 - Review article

AN - SCOPUS:85107910708

SN - 2196-3053

VL - 8

SP - 97

EP - 110

JO - Current Treatment Options in Allergy

JF - Current Treatment Options in Allergy

IS - 2

ER -

Latest Developments in the Management of Nut Allergies

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this